Top

Published in:

Open Access 01-02-2021 | Acute Myeloid Leukemia | Letter to the Editor

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Authors: Rabia Shahswar, Gernot Beutel, Razif Gabdoulline, Christian Koenecke, Dominik Markel, Matthias Eder, Michael Stadler, Gudrun Gohring, Brigitte Schlegelberger, Arne Trummer, Juergen Krauter, Felicitas Thol, Michael Heuser

Published in: Annals of Hematology | Issue 2/2021

Excerpt

To the Editor, …

Available only for authorised users

Bhola PD, Letai A (2016) Mitochondria-judges and executioners of cell death sentences. Mol Cell 61(5):695–704. https://doi.org/10.1016/j.molcel.2016.02.019CrossRefPubMedPubMedCentral

Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R, Falotico N, Leverson J, Humerickhouse R, Mabry M, Stone R, Kantarjian H, Letai A (2016) Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukaemia. Cancer Discov 6(10):1106–1117.4. https://doi.org/10.1158/2159-8290.CD-16-0313CrossRefPubMedPubMedCentral

Wei AH et al (2020) Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. https://doi.org/10.1182/blood.2020004856

DiNardo CD et al (2019) Venetoclax combined with Decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17. https://doi.org/10.1182/blood-2018-08-868752CrossRefPubMedPubMedCentral

Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, Wierzbowska A, Buske C (2020) Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol S0923-7534(20):36079–36078. https://doi.org/10.1016/j.annonc.2020.02.018CrossRef

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311–322. https://doi.org/10.1056/NEJMoa1513257CrossRefPubMed

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

Cairo M, Bishop M (2004) Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127:3–11. https://doi.org/10.1111/j.1365-2141.2004.05094.xCrossRefPubMed

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196CrossRefPubMedPubMedCentral

10.

Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, Fakouhi KM, Humerickhouse R, Hong WJ, Hayslip J, Roboz GJ (2019) Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol 37(15):1277–1284. https://doi.org/10.1200/JCO.18.01600CrossRefPubMedPubMedCentral

Title: Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up
Authors: Rabia Shahswar
Gernot Beutel
Razif Gabdoulline
Christian Koenecke
Dominik Markel
Matthias Eder
Michael Stadler
Gudrun Gohring
Brigitte Schlegelberger
Arne Trummer
Juergen Krauter
Felicitas Thol
Michael Heuser
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Acute Myeloid Leukemia
Tumor Lysis Syndrome
Published in: Annals of Hematology / Issue 2/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04181-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL

Primary pulmonary diffuse large B cell lymphoma presenting as bulky bilateral lung tumors

Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in sickle cell disease and its association with disease-related morbidities

Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Newly diagnosed isolated myeloid sarcoma–paired NGS panel analysis of extramedullary tumor and bone marrow

Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page